Literature DB >> 16044133

Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation.

C C Dvorak1, W J Steinbach, J M Y Brown, R Agarwal.   

Abstract

Invasive fungal infections (IFI) are the leading cause of infectious mortality in adult patients undergoing hematopoietic cell transplantation (HCT) after myeloablative conditioning, but the extent of this problem in the pediatric population is unclear. We retrospectively examined risk factors for IFI among 120 consecutive pediatric patients undergoing allogeneic HCT at a single center. The incidence of proven or probable IFI in pediatric patients during the first year after allogeneic HCT was 13%, comparable to the rate reported in adult patients; however, unlike IFI in adult patients, the majority of IFI in children occurred within the first month after transplantation. The primary risk factors for IFI were duration of neutropenia, age greater than 10 years, transplant for severe aplastic anemia or Fanconi anemia, and high-dose corticosteroid administration for 10 days or longer. IFI were more likely to be successfully treated (42%, 5/12 patients) in pediatric HCT recipients when compared to previous reports of adult recipients. Nonrelapse mortality was estimated at 17% (20/120 patients) after allogeneic HCT, of which 35% (seven patients) were directly attributed to IFI. Thus, IFI is a significant cause of nonrelapse mortality in children undergoing allogeneic HCT and more effective strategies are needed to prevent and treat IFI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044133     DOI: 10.1038/sj.bmt.1705113

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  27 in total

1.  Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients.

Authors:  J A Hol; T F W Wolfs; M B Bierings; C A Lindemans; A B J Versluys; A Wildt de; C E Gerhardt; J J Boelens
Journal:  Bone Marrow Transplant       Date:  2013-10-14       Impact factor: 5.483

2.  Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  K Yoshikawa; Y Nakazawa; Y Katsuyama; K Hirabayashi; S Saito; T Shigemura; M Tanaka; R Yanagisawa; K Sakashita; K Koike
Journal:  Infection       Date:  2014-02-25       Impact factor: 3.553

3.  New Insights Into Multicenter PICU Mortality Among Pediatric Hematopoietic Stem Cell Transplant Patients.

Authors:  Matt S Zinter; Christopher C Dvorak; Aaron Spicer; Morton J Cowan; Anil Sapru
Journal:  Crit Care Med       Date:  2015-09       Impact factor: 7.598

Review 4.  Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.

Authors:  Christopher C Dvorak; Brian T Fisher; Lillian Sung; William J Steinbach; Michael Nieder; Sarah Alexander; Theoklis E Zaoutis
Journal:  Pediatr Blood Cancer       Date:  2011-11-18       Impact factor: 3.167

5.  Immunosuppressive compounds exhibit particular effects on functional properties of human anti-Aspergillus Th1 cells.

Authors:  Lars Tramsen; Stanislaw Schmidt; Frauke Roeger; Ralf Schubert; Emilia Salzmann-Manrique; Jean-Paul Latgé; Thomas Klingebiel; Thomas Lehrnbecher
Journal:  Infect Immun       Date:  2014-04-07       Impact factor: 3.441

Review 6.  Advancements in the treatment of pediatric acute leukemia and brain tumor - continuous efforts for 100% cure.

Authors:  Hee Young Ju; Che Ry Hong; Hee Young Shin
Journal:  Korean J Pediatr       Date:  2014-10-31

7.  Impact of the D-index deduced from duration and intensity of neutropenia following chemotherapy on the risk of invasive fungal infection in pediatric acute myeloid leukemia.

Authors:  Hirozumi Sano; Ryoji Kobayashi; Daisuke Suzuki; Daiki Hori; Kenji Kishimoto; Kunihiko Kobayashi
Journal:  Int J Hematol       Date:  2018-03-21       Impact factor: 2.490

8.  Pediatric antifungal utilization: new drugs, new trends.

Authors:  Priya A Prasad; Susan E Coffin; Kateri H Leckerman; Thomas J Walsh; Theoklis E Zaoutis
Journal:  Pediatr Infect Dis J       Date:  2008-12       Impact factor: 2.129

9.  Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation.

Authors:  Carol Garcia-Vidal; Arlo Upton; Katharine A Kirby; Kieren A Marr
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

Review 10.  Fungal infections in children with haematologic malignancies and stem cell transplant recipients.

Authors:  William R Otto; Abby M Green
Journal:  Br J Haematol       Date:  2020-03-11       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.